Press Releases

    • January 27, 2023

    Nemaura Medical Announces Pricing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement

    LOUGHBOROUGH, Jan. 27, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology...

    Read more
    January 26, 2023

    Nemaura Medical Receives First Purchase Order from U.S. Health Provider HealthFleet

    Nemaura to integrate its proBEATTM glucose sensors with HealthFleet’s proven RestoreHealth wellness program targeted at U.S. market. LOUGHBOROUGH, Jan....

    Read more
    January 24, 2023

    Nemaura Medical Reports Initial Patient Data from UK NHS Miboko Study that Demonstrates Weight Loss in 100% of Participants

    Average weight loss of 3.7 pounds and an average BMI reduction of 0.6 after 10 weeks in initial patients....

    Read more
    November 29, 2022

    Nemaura Commences Pilot Program of Miboko with the NHS in the United Kingdom

    LOUGHBOROUGH, Nov. 29, 2022 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD)(“Nemaura” or the “Company”), a medical technology company...

    Read more
    November 15, 2022

    Nemaura Medical Reports Fiscal Second Quarter 2023 Results and Provides Business Update

    Loughborough, England, Nov. 15, 2022 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical...

    Read more
    September 27, 2022

    Nemaura and EVERSANA sign preliminary agreement for large-scale launch of Nemaura’s Diabetes Management Program in the U.S.

    CHICAGO and LOUGHBOROUGH, Sept. 27, 2022 (GLOBE NEWSWIRE) — Nemaura Medical, Inc.(NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on...

    Read more
    August 15, 2022

    Nemaura Medical Reports Fiscal First Quarter 2023 Results and Provides Business Update

    Loughborough, England, Aug. 15, 2022 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical...

    Read more
    July 21, 2022

    Nemaura Medical Granted UK Trademark “Meta Score,” a Digital Biomarker Term for its Metabolic Health Program

    Loughborough, England – July 21, 2022 (GlobeNewswire) – Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical...

    Read more
    June 30, 2022

    Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2022

    Loughborough, England, June 30, 2022 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical...

    Read more
    May 23, 2022

    Nemaura Medical Strengthens Balance Sheet with Further Non-Dilutive Funding

    Loughborough, England, May 23, 2022 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on...

    Read more